Oci ly 19

Manufactured by American Type Culture Collection

Sourced in United States

The OCI-LY-19 is a laboratory equipment used for cell culture applications. It is designed to provide a controlled environment for the growth and maintenance of cells in a laboratory setting. The core function of the OCI-LY-19 is to maintain optimal temperature, humidity, and CO2 levels required for cell culture.

Automatically generated - may contain errors

Lab products found in correlation

5 protocols using oci ly 19

DLBCL Cell Line and Primary Sample Collection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human DLBCL cell lines OCI‐Ly19, OCI‐Ly1, OCI‐Ly3, OCI‐Ly10 and SU‐DHL‐4 were purchased from ATCC (Rockefeller, MD, USA) and DLBCL cell lines were grown in RPMI‐1640 medium (Gibco, Billings, MT, USA). OCI‐Ly3 cells were cultured in IMDM (Gibco). Supplemented with 10% fetal bovine serum (HyClone, Thermo Scientific, Waltham, MA, USA) at 37 °C in a humidified CO₂ incubator. The primary DLBCL samples (n = 12) were obtained from the Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University (Hangzhou, China) between 2021 and 2022. This study was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University. The study methodologies conformed to the standards set by the Declaration of Helsinki and the experiments were undertaken with the understanding and written consent of each subject.

Shi Y., Ye J., Shen H., Xu Y., Wan R., Ye X., Jin J, & Xie W. (2022). Apatinib enhances chemosensitivity of ABT‐199 in diffuse large B‐cell lymphoma. Molecular Oncology, 16(20), 3735-3753.

+ Open protocol

+ Expand

DLBCL Cell Lines Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The DLBCL cell lines SU-DHL-4, OCI-LY-1, OCI-LY-19 (GCB-DLBCL) and SU-DHL-2 (ABC-DLBCL) cells were purchased from ATCC and cultured with RPMI 1640 medium (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% inactived fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 unit/ml penicillin, and 10 μg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in a humidified atmosphere of 5% CO₂ at 37°C.

Jiang L., Wen C., Zhou H., Liu A., Zhang H., Chen X., Ding W., Liu J, & Shi X. (2022). Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells. Cancer Biology & Therapy, 23(1), 319-327.

+ Open protocol

+ Expand

DLBCL Cell Line Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The DLBCL cell lines SU-DHL-4, OCI-LY-1, OCI-LY-19 (GCB-DLBCL) and SU-DHL-2 (ABC-DLBCL) were purchased from ATCC (Manassas, VA) and incubated in RPMI 1640 medium (LifeTechnologies, Waltham, MA) supplemented with 10% fetal calf serum (Hyclone, Waltham, MA), 100 unit/ml penicillin, and 0.1 mg/ml streptomycin. Cells were incubated at 37 °C and in water vapor–saturated air with 5% CO₂ at one atmospheric pressure.

Jiang L., Sun Y., Wang J., He Q., Chen X., Lan X., Chen J., Dou Q.P., Shi X, & Liu J. (2019). Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma. Journal of Experimental & Clinical Cancer Research : CR, 38, 453.

+ Open protocol

+ Expand

Culturing 16 DLBCL Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The 16 DLBCL cell lines (DOHH2, HT, OCI-LY19, DB, OCI-LY1, SUDHL-4, SUDHL-5, SUDHL-10, NUDHL-1, OCI-LY7, WSU-DLCL2, SUDHL-6, NUDUL-1, U2932, OCI-LY3, and RI-1) were purchased from the American Type Culture Collection or from DSMZ (Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany). They were grown in RPMI-1640 Glutamax medium (Gibco, Invitrogen, Cergy Pontoise, France), supplemented with 10% fetal bovine serum (FBS) (PAA laboratory GmbH, Pasching, Austria) (U2932, SUDHL-4, HT, DOHH2, SUDHL-10, RI-1, and WSU-DLCL2 cells), 20% FBS (OCI-LY3, DB, SUDHL-5, NUDHL-1, and SUDHL-6 cells), or 15% FBS (NUDUL-1 cells). OCI-LY1, and OCI-LY7 cells were cultured in IMDM Glutamax (Gibco, Invitrogen, Cergy Pontoise, France), supplemented with 20% FBS, and OCI-LY19 cells in MEM alpha modified Glutamax (Gibco, Invitrogen, Cergy Pontoise, France) with 20% FBS. Cultures were maintained at 37 °C in a humidified atmosphere with 5% CO₂. Contamination by Mycoplasma species was regularly monitored.

Devin J., Kassambara A., Bruyer A., Moreaux J, & Bret C. (2019). Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact. Journal of Clinical Medicine, 8(7), 1074.

+ Open protocol

+ Expand

Generating WASp-Sufficient and Deficient Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

To generate WASp-sufficient (WT) and WASp-deficient cell-pairs, we used human Th (T helper)- and B cells, normal or malignant. These are: (1) normal Th-cells (HTLV1-immortalized, ND1) described previously [40 (link)], (2) leukemic Th-cells (Jurkat), (3) normal-donor (ND03179) and WAS patient-derived B cells (EBV-immortalized), harboring E133K (WAS03; ID00003) and V75M (WAS68; GM21868) missense mutations were purchased (Coriell Institute, Camden, NJ). (4) B cell lymphomas: Farage, HBL-1, OCI-Ly19, (Diffuse large B cell lymphomas, DLBCLs), Raji (Burkitt lymphoma), were either purchased from American Type Culture Collection (Manassas, VA) or a gift from Dr. S. Janz (Univ. of Iowa). To generate an isogenic WASp-deficient cell-line pair, wild-type (WT) cells were transfected with 2 μg of WASP-CRISPR/CAS9 GFP-tagged plasmid (sc-400712-KO-2, Santa Cruz biotechnology, Santa Cruz, CA) using Amaxa-nucleofaction. GFP⁺ cells were FACS-sorted, plated into 96-well plates by serial dilution, and samples screened by PCR, DNA-sequencing, and Western blot to verify complete WAS knock-out (WKO) and WASp-depletion, as we previously described [40 (link)]. Mycoplasma contamination was ruled out for all cell lines used, prior to conducting downstream assays (Supplementary Fig. 1A)

Han S.S., Wen K.K, & Vyas Y.M. (2020). Deficiency of Wiskott–Aldrich syndrome protein has opposing effect on the pro-oncogenic pathway activation in nonmalignant versus malignant lymphocytes. Oncogene, 40(2), 345-354.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!